国际麻醉学与复苏杂志
國際痳醉學與複囌雜誌
국제마취학여복소잡지
INTERNATIONAL JOURNAL OF ANESTHESIOLOGY AND RESUSCITATION
2014年
5期
385-387,396
,共4页
李红伟%原大江%徐文会%王海霞
李紅偉%原大江%徐文會%王海霞
리홍위%원대강%서문회%왕해하
全麻%尿管相关膀胱刺激症%躁动%地佐辛
全痳%尿管相關膀胱刺激癥%躁動%地佐辛
전마%뇨관상관방광자격증%조동%지좌신
General anesthesia%Catheter-related bladder discomfort%Agitation%Dezocine
目的 评价不同剂量地佐辛对全麻恢复期尿管相关膀胱刺激症(catheter-related bladder discomfort,CRBD)的治疗效果. 方法 择期全麻下行后路椎体间植骨融合术男性患者,美国麻醉医师协会(ASA)分级Ⅰ或Ⅱ级,年龄40岁～65岁,体重指数在18～25之间,选择送达麻醉恢复室(post anesthesia care unit,PACU)后主诉CRBD患者100例,采用随机数字表法将患者分为4组(每组25例),对照组(C组)静脉注射生理盐水2 ml,不同剂量地佐辛组(D1～3组)分别静脉注射地佐辛5、7.5、10 mg.分别于用药后即刻(T0)、1(T1)、2 h(T2)和6 h(T3),评估患者CRBD的程度和镇静程度,记录手术时间、术中舒芬太尼用量、PACU芬太尼用量以及副作用发生情况. 结果 T1、T2、T3时刻,C组CRBD程度[(轻度8例、中度15例、重度2例)、(无症状患者1例、轻度12例、中度11例、重度1例)、(无症状患者3例、轻度14例、中度7例、重度1例)]与D1组[(轻度15例、中度9例、重度1例)、(无症状患者7例、轻度14例、中度4例)、(无症状患者10例、轻度14例、中度1例)]、D2组[(无症状者1例、轻度17例、中度6例、重度1例)、(无症状患者13例、轻度10例、中度2例)、(无症状患者14例、轻度10例、中度1例)]、D3组[(无症状患者1例、轻度17例、中度7例)、(无症状者12例、轻度12例、中度1例)、(无症状患者15例、轻度9例、中度1例)]比较,差异有统计学意义(P＜0.05),D1组CRBD程度与D2组、D3组比较,差异有统计学意义(P＜0.05);T1、T2时刻,C组镇静程度[(无症状患者23例、轻度2例)、(无症状者25例)]与D1组[(无症状患者10例、轻度15例)、(无症状患者7例、轻度18例)]、D2组[(无症状患者2例、轻度21例、中度2例)、(无症状患者3例、轻度22例)]、D3组[(无症状患者1例、轻度21例、中度3例)、(无症状患者2例、轻度22例、中度1例)]比较,差异有统计学意义(P＜0.05). 结论 地佐辛可以缓解CRBD,其适宜剂量为7.5 mg.
目的 評價不同劑量地佐辛對全痳恢複期尿管相關膀胱刺激癥(catheter-related bladder discomfort,CRBD)的治療效果. 方法 擇期全痳下行後路椎體間植骨融閤術男性患者,美國痳醉醫師協會(ASA)分級Ⅰ或Ⅱ級,年齡40歲～65歲,體重指數在18～25之間,選擇送達痳醉恢複室(post anesthesia care unit,PACU)後主訴CRBD患者100例,採用隨機數字錶法將患者分為4組(每組25例),對照組(C組)靜脈註射生理鹽水2 ml,不同劑量地佐辛組(D1～3組)分彆靜脈註射地佐辛5、7.5、10 mg.分彆于用藥後即刻(T0)、1(T1)、2 h(T2)和6 h(T3),評估患者CRBD的程度和鎮靜程度,記錄手術時間、術中舒芬太尼用量、PACU芬太尼用量以及副作用髮生情況. 結果 T1、T2、T3時刻,C組CRBD程度[(輕度8例、中度15例、重度2例)、(無癥狀患者1例、輕度12例、中度11例、重度1例)、(無癥狀患者3例、輕度14例、中度7例、重度1例)]與D1組[(輕度15例、中度9例、重度1例)、(無癥狀患者7例、輕度14例、中度4例)、(無癥狀患者10例、輕度14例、中度1例)]、D2組[(無癥狀者1例、輕度17例、中度6例、重度1例)、(無癥狀患者13例、輕度10例、中度2例)、(無癥狀患者14例、輕度10例、中度1例)]、D3組[(無癥狀患者1例、輕度17例、中度7例)、(無癥狀者12例、輕度12例、中度1例)、(無癥狀患者15例、輕度9例、中度1例)]比較,差異有統計學意義(P＜0.05),D1組CRBD程度與D2組、D3組比較,差異有統計學意義(P＜0.05);T1、T2時刻,C組鎮靜程度[(無癥狀患者23例、輕度2例)、(無癥狀者25例)]與D1組[(無癥狀患者10例、輕度15例)、(無癥狀患者7例、輕度18例)]、D2組[(無癥狀患者2例、輕度21例、中度2例)、(無癥狀患者3例、輕度22例)]、D3組[(無癥狀患者1例、輕度21例、中度3例)、(無癥狀患者2例、輕度22例、中度1例)]比較,差異有統計學意義(P＜0.05). 結論 地佐辛可以緩解CRBD,其適宜劑量為7.5 mg.
목적 평개불동제량지좌신대전마회복기뇨관상관방광자격증(catheter-related bladder discomfort,CRBD)적치료효과. 방법 택기전마하행후로추체간식골융합술남성환자,미국마취의사협회(ASA)분급Ⅰ혹Ⅱ급,년령40세～65세,체중지수재18～25지간,선택송체마취회복실(post anesthesia care unit,PACU)후주소CRBD환자100례,채용수궤수자표법장환자분위4조(매조25례),대조조(C조)정맥주사생리염수2 ml,불동제량지좌신조(D1～3조)분별정맥주사지좌신5、7.5、10 mg.분별우용약후즉각(T0)、1(T1)、2 h(T2)화6 h(T3),평고환자CRBD적정도화진정정도,기록수술시간、술중서분태니용량、PACU분태니용량이급부작용발생정황. 결과 T1、T2、T3시각,C조CRBD정도[(경도8례、중도15례、중도2례)、(무증상환자1례、경도12례、중도11례、중도1례)、(무증상환자3례、경도14례、중도7례、중도1례)]여D1조[(경도15례、중도9례、중도1례)、(무증상환자7례、경도14례、중도4례)、(무증상환자10례、경도14례、중도1례)]、D2조[(무증상자1례、경도17례、중도6례、중도1례)、(무증상환자13례、경도10례、중도2례)、(무증상환자14례、경도10례、중도1례)]、D3조[(무증상환자1례、경도17례、중도7례)、(무증상자12례、경도12례、중도1례)、(무증상환자15례、경도9례、중도1례)]비교,차이유통계학의의(P＜0.05),D1조CRBD정도여D2조、D3조비교,차이유통계학의의(P＜0.05);T1、T2시각,C조진정정도[(무증상환자23례、경도2례)、(무증상자25례)]여D1조[(무증상환자10례、경도15례)、(무증상환자7례、경도18례)]、D2조[(무증상환자2례、경도21례、중도2례)、(무증상환자3례、경도22례)]、D3조[(무증상환자1례、경도21례、중도3례)、(무증상환자2례、경도22례、중도1례)]비교,차이유통계학의의(P＜0.05). 결론 지좌신가이완해CRBD,기괄의제량위7.5 mg.
Objective To evaluate the efficacy of different doses of dezocine on catheter-related bladder discomfort (CRBD) of patients with operation under general anesthesia.Methods Male patients (40 y-65 y) who suffered posterior lumbar interbody fusionare were selected in this research.Their body mass index was between 18-25 with ASA Ⅰ or Ⅱ grade.One hundred cases of patients who complained CRBD in post anesthesia care unit (PACU) were chosen and randomly divided into 4 groups (n=25).The control group patients (group C) were intravenously injected with saline 2 ml,while the experimental group patients (groups D1-D3) with different doses of dezocine were intravenously injected with dezocine 7.5 mg and 10 mg respectively.Immediately after administration (T0),and at 1 (T1),2 h (T2) and 6 h (T3),the CRBD and sedation level were assessed.Moreover,the operation time,intraoperative dosage of sufentanil,dosage of fentanyl in PACU,and adverse reactions were all recorded.Results CRBD levels were significantly higher in group C [(8 mild,15 moderate and 2 severe) at T1 (1 asymptomatic,12 mild,11 moderate and 1 severe) at T2,(3 asymptomatic,14 mild,7 moderate and 1 severe) at T3] than that in group D1 [(15 mild,9 moderate and 1 severe) at T1 (7 asymptomatic,14 mild and 4 moderate) at T2,(10 asymptomatic,14 mild and 1 moderate) at T3],group D2 [(1 asymptomatic,17 mild,6 moderate and 1 severe) at T1,(13 asymptomatic,10 mild and 2 moderate) at T2,(14 asymptomatic,10 mild and 1 moderate) at T3] and group D3 [(1 asymptomatic,17 mild,7 moderate) at T1,(12 asymptomatic,12 mild and 1 moderate) at T2,(15 asymptomatic,9 mild and 1 moderate) at T3] (P＜0.05).Compared with that of group D1,at T1,T2,and T3,CRBD levels in group D2 and D3 were decreased (P＜0.05).Sedation levels in group D1 [(10 asymptomatic and 15 mild) at T1,(7 asymptomatic and 18 mild) at T2],D2 [(2 asymptomatic,21 mild and 2 moderate) at T1,(3 asymptomatic and 22 mild) at T2] and D3 [(1 asymptomatic,21 mild and 3 moderate) at T1,(2 asymptomatic,22 mild and 1 moderate) at T2] were increased as compared with that of C group [(23 asymptomatic and 2 mild) at T1,(25 asymptomatic) at T2] (P＜0.05).Conclusions Dezocine can relieve CRBD,which suitable dose is 7.5 mg.
